(ABT) Abbott Laboratories - Ratings and Ratios
Pharmaceuticals, Diagnostics, Nutrition, Devices
Dividends
| Dividend Yield | 1.89% |
| Yield on Cost 5y | 2.41% |
| Yield CAGR 5y | 11.18% |
| Payout Consistency | 92.6% |
| Payout Ratio | 49.8% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 19.5% |
| Value at Risk 5%th | 30.0% |
| Relative Tail Risk | -6.65% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.35 |
| Alpha | 2.76 |
| CAGR/Max DD | 0.35 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.306 |
| Beta | 0.246 |
| Beta Downside | 0.448 |
| Drawdowns 3y | |
|---|---|
| Max DD | 20.88% |
| Mean DD | 6.72% |
| Median DD | 5.74% |
Description: ABT Abbott Laboratories December 01, 2025
Abbott Laboratories (NYSE: ABT) is a diversified health-care company that operates across four core segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The firm markets a broad portfolio ranging from generic drugs for gastrointestinal, metabolic, and cardiovascular conditions to point-of-care diagnostic platforms, infant nutrition, and cardiovascular-plus-neuromodulation devices.
In fiscal 2023 Abbott reported revenue of approximately $43 billion, an operating margin of about 28 %, and earnings per share of $2.85, supported by a 7 % year-over-year increase in diagnostics sales driven largely by molecular testing and rapid-test platforms. The company’s R&D spend was $2.5 billion (≈5.8 % of revenue), reflecting continued investment in next-generation device and assay technologies.
Key drivers of Abbott’s outlook include the aging U.S. and global populations, which raise demand for chronic-disease therapeutics and home-based monitoring; sustained growth in health-care spending (≈5 % CAGR worldwide); and the industry-wide shift toward outpatient and point-of-care services, which benefits Abbott’s diagnostic and device segments. A potential risk is heightened regulatory scrutiny on generic pricing and device approvals, which could compress margins if not managed.
For a deeper quantitative assessment, you might explore ValueRay’s detailed valuation models for ABT.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (13.98b TTM) > 0 and > 6% of Revenue (6% = 2.63b TTM) |
| FCFTA 0.08 (>2.0%) and ΔFCFTA -0.51pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 23.39% (prev 21.59%; Δ 1.80pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.11 (>3.0%) and CFO 9.12b <= Net Income 13.98b (YES >=105%, WARN >=100%) |
| Net Debt (5.43b) to EBITDA (11.72b) ratio: 0.46 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.70 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.75b) change vs 12m ago 0.06% (target <= -2.0% for YES) |
| Gross Margin 53.98% (prev 50.98%; Δ 3.01pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 55.31% (prev 55.43%; Δ -0.12pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 19.04 (EBITDA TTM 11.72b / Interest Expense TTM 451.0m) >= 6 (WARN >= 3) |
Altman Z'' 5.59
| (A) 0.12 = (Total Current Assets 24.84b - Total Current Liabilities 14.58b) / Total Assets 84.18b |
| (B) 0.58 = Retained Earnings (Balance) 49.10b / Total Assets 84.18b |
| (C) 0.11 = EBIT TTM 8.59b / Avg Total Assets 79.27b |
| (D) 2.06 = Book Value of Equity 67.83b / Total Liabilities 32.92b |
| Total Rating: 5.59 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 64.89
| 1. Piotroski 5.0pt |
| 2. FCF Yield 3.01% |
| 3. FCF Margin 15.78% |
| 4. Debt/Equity 0.25 |
| 5. Debt/Ebitda 0.46 |
| 6. ROIC - WACC (= 3.74)% |
| 7. RoE 28.24% |
| 8. Rev. Trend -8.51% |
| 9. EPS Trend -34.92% |
What is the price of ABT shares?
Over the past week, the price has changed by -2.96%, over one month by +0.43%, over three months by -5.49% and over the past year by +10.26%.
Is ABT a buy, sell or hold?
- Strong Buy: 12
- Buy: 7
- Hold: 9
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ABT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 144.4 | 15.5% |
| Analysts Target Price | 144.4 | 15.5% |
| ValueRay Target Price | 124.9 | -0.2% |
ABT Fundamental Data Overview November 29, 2025
P/E Trailing = 16.1732
P/E Forward = 22.6244
P/S = 5.117
P/B = 4.3866
P/EG = 4.1675
Beta = 0.719
Revenue TTM = 43.84b USD
EBIT TTM = 8.59b USD
EBITDA TTM = 11.72b USD
Long Term Debt = 11.60b USD (from longTermDebt, last quarter)
Short Term Debt = 1.34b USD (from shortTermDebt, last quarter)
Debt = 12.94b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.43b USD (from netDebt column, last quarter)
Enterprise Value = 229.55b USD (224.35b + Debt 12.94b - CCE 7.73b)
Interest Coverage Ratio = 19.04 (Ebit TTM 8.59b / Interest Expense TTM 451.0m)
FCF Yield = 3.01% (FCF TTM 6.92b / Enterprise Value 229.55b)
FCF Margin = 15.78% (FCF TTM 6.92b / Revenue TTM 43.84b)
Net Margin = 31.88% (Net Income TTM 13.98b / Revenue TTM 43.84b)
Gross Margin = 53.98% ((Revenue TTM 43.84b - Cost of Revenue TTM 20.18b) / Revenue TTM)
Gross Margin QoQ = 55.75% (prev 56.44%)
Tobins Q-Ratio = 2.73 (Enterprise Value 229.55b / Total Assets 84.18b)
Interest Expense / Debt = 0.34% (Interest Expense 44.0m / Debt 12.94b)
Taxrate = 24.59% (536.0m / 2.18b)
NOPAT = 6.48b (EBIT 8.59b * (1 - 24.59%))
Current Ratio = 1.70 (Total Current Assets 24.84b / Total Current Liabilities 14.58b)
Debt / Equity = 0.25 (Debt 12.94b / totalStockholderEquity, last quarter 50.95b)
Debt / EBITDA = 0.46 (Net Debt 5.43b / EBITDA 11.72b)
Debt / FCF = 0.79 (Net Debt 5.43b / FCF TTM 6.92b)
Total Stockholder Equity = 49.50b (last 4 quarters mean from totalStockholderEquity)
RoA = 16.60% (Net Income 13.98b / Total Assets 84.18b)
RoE = 28.24% (Net Income TTM 13.98b / Total Stockholder Equity 49.50b)
RoCE = 14.06% (EBIT 8.59b / Capital Employed (Equity 49.50b + L.T.Debt 11.60b))
RoIC = 10.29% (NOPAT 6.48b / Invested Capital 62.93b)
WACC = 6.56% (E(224.35b)/V(237.29b) * Re(6.92%) + D(12.94b)/V(237.29b) * Rd(0.34%) * (1-Tc(0.25)))
Discount Rate = 6.92% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 33.33 | Cagr: 0.03%
[DCF Debug] Terminal Value 77.94% ; FCFE base≈6.74b ; Y1≈6.59b ; Y5≈6.67b
Fair Price DCF = 68.12 (DCF Value 118.45b / Shares Outstanding 1.74b; 5y FCF grow -3.37% → 3.0% )
EPS Correlation: -34.92 | EPS CAGR: -0.41% | SUE: 0.0 | # QB: 0
Revenue Correlation: -8.51 | Revenue CAGR: -0.23% | SUE: -0.19 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.20 | Chg30d=-0.004 | Revisions Net=-5 | Analysts=20
EPS next Year (2026-12-31): EPS=5.68 | Chg30d=-0.000 | Revisions Net=-1 | Growth EPS=+10.1% | Growth Revenue=+7.9%
Additional Sources for ABT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle